DeepMed Research

Pvs230D1-EPA/Matrix-M

Generic Name: Pvs230D1-EPA/Matrix-M

Clinical Trials

Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults

Phase 1

Active, not recruiting

Conditions: Malaria

Interventions: Drug: Pvs230D1-EPA/Matrix-M

First Posted Date: 2023-06-22

Last Posted Date: 2025-04-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 105

Registration Number: NCT05913973

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy